Drug having regulatory cell ligand contained in liposome

ABSTRACT

A liposome containing a regulatory cell ligand such as α-galactosyl ceramide or β-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.

TECHNICAL FIELD

The present invention relates to a drug having a regulatory cell ligandcontained in a liposome, and more particularly relates to a drug forimmune diseases such as allergic diseases and autoimmune diseases.

BACKGROUND ART

Immune diseases such as allergic diseases, autoimmune diseases andgraft-versus-host diseases (GVHD) are the disease caused by abnormalityor incompatibility of the immune system. Among them, patients with someillness of allergic disease tend to increase year by year, and it hasbeen reported that 70% of Japanese people have already affected withsome allergic disease. A category of the allergic diseases is broad andincludes asthma, atopic dermatitis, pollinosis, food allergy andallergodermia. Many of the patients with allergy are known to developvarious allergic diseases sequentially, which is referred to as allergymarch. In recent years in Japan, the patients with pollinosiss orpediatric atopic asthma complicated with allergic rhinitis or allergicconjunctivitis have increased markedly. As a reason for this, it hasbeen thought that change of life environment, particularly the change ofimmunological environment (decrease of bacterial infection, increase ofhouse dust density in an airtight house) in infant in which the immunesystem is formed may increase the production of IgE antibody. It isevident that narrowly defined allergic diseases such as allergicrhinitis, allergic conjunctivitis and atopic asthma are caused by type Iallergic reaction in which the IgE antibody and Th2 cells which inducethe production of the antibody are involved. It has been frequentlyreported that the IgE antibody and the predominant Th2 cells are deeplyinvolved during the stage of occurrence of other various allergicdiseases other than them. From the above, it is predicted that depressedproduction of the IgE antibody which is responsible for the type Iallergic reaction and inhibition of Th2 cell differentiation can bepromising procedures for therapy of the allergic diseases. For thepatients with allergic disease predicted to further increase in thefuture, a causal therapy by medicaments made based on allergy occurrencemechanisms or a preventive (vaccine) method which reduces the allergyfrom occurring are thought to be somehow effective. It is necessary toassure high safety profile (low side effect) for remedy.

A humanized anti-IgE antibody (rhuMAb-E25, Genentech Inc.) has beenshown to be highly effective in clinical trials with the patients withatopic asthma (see Non-patent literature 1). In an attempt to inhibitthe production of an antigen specific IgE antibody using an artificialcompound, an immune response of Th1 type was induced in BALB/c miceimmunized with a plasmid DNA in which cedar pollen antigen Cry j1 genehad been incorporated. As a result, an IgG2a antibody was produced, andeven when the Cry j1 antigen and alum were boosted, the production ofIgGl and IgE antibodies was suppressed (see Non-patent literature 2).When the mouse was immunized with an OVA-IL-12 fusion protein, theimmune response of OVA specific Th1 type was induced. Its efficiency wasmuch higher than in the case of being immunized with a mixture solutionof OVA and IL-12, and the OVA specific IgG2a antibody was produced (seeNon-patent literature 3). This report indicates that the response can bebiased to the Thl type by the immunization with a complex of the antigenand a cytokine inducer and along with it the antigen specific productionof the IgE antibody can be suppressed.

To prevent the allergic disease or lead it to cure, it can be aneffective procedure to control regulatory cells which suppress thedifferentiation, proliferation and functions of Th cells and IgEantibody producing B cells. An NKT cell is believed to be one of theregulatory cells which plays an important role in cancer cells,parasites and protozoa, and for eliminating intracellularly infectedbacteria such as Listeria and tuberculosis germs (see Non-patentliterature 4). It has been demonstrated that the NKT cell is anintermediate TCR cell (TCR_(int) cell) which expresses a T cell receptor(TCR) moderately, and is the cell analogous to an Natural Killer (NK)cell in points of exhibiting a large granular lymphocyte (LGL)-likemorphology, constitutively expressing IL-2R β chain on the surface andhaving perforin granules, but is absolutely different from the NK cellin point of having TCR (see Non-patent literature 5). A Vα14³⁰ NKT cellis one of subsets of the above NKT cells, many of the Vα14⁺ NKT cellsexpress Vα14Jα281 mRNA and have this as TCR a chain. A Vα24JaQ chain, ahuman homolog which is homologous to the murine Vα14Jα281 chain ispresent at 20 to 50% in peripheral blood CD4⁻/CD8⁻ T cells in healthydonors (see Non-patent literature 6).

α-Galactosyl ceramide which is a ligand compound of these NKT cellsinduces the cytokine production of both IFN-γ and IL-4. Thus, it hasbeen shown that the NKT cell is the regulatory cell for thedifferentiation of Th1/Th2 (see Non-patent literature 7). Whenα-galactosyl ceramide was administered to C57BL/6 mice, the productionof IgE antibody induced by DNP-OVA and alum was inhibited. In the sameexperiment using mice deleting the Vα14-NKT cells, the production of IgEantibody was not inhibited (see Non-patent literature 8). In theexperiments in which α-galactosyl ceramide compound was administered toNOD mice, a type I diabetes model, the symptomatic improvement wasobserved. Thus, the possibility has been suggested that the Vα14-NKTcell augments the immune response via Th2 cells (see Non-patentliterature 9). However, the effect obtained by α-galactosyl ceramidecompound alone is limited, and further improvement of medicinal efficacyhas been required.

Meanwhile, substances of β-galactosyl ceramide and β-glycosyl ceramideare present in vivo, but it has been shown that they have much loweractivity compared with immunopotentiation and anti-tumor effects ofα-galactosyl ceramide compound (see Non-patent literatures 10 to 12, andPatent document 1).

Additionally, the NKT cell has been known to effectively serve forautoimmune diseases (see Non-Patent literatures 13 to 16). Therefore, ifimmunosuppressive functions, e.g., the production of IL-10 in the NKTcells can be selectively augmented, it is thought to be effective forthe treatment of not only the allergic diseases but also the otherimmune diseases such as autoimmune diseases and GVHD. However, no ligandwhich alone can selectively augment the immunosuppressive function ofthe NKT cell has been known. No liposome has been used for such apurpose.

Patent document 1: JP Hei-1-93562 A, Publication;

Non-patent literature 1: Immunopharmacology, 48:307 (2000);Non-patent literature 2: Immunology, 99:179(2000);Non-patent literature 3: J. Immunol., 158:4137 (1997);Non-patent literature 4: Clin. Immunol., 28, 1069 (1996);Non-patent literature 5: J. Immunol., 155, 2972 (1995);Non-patent literature 6: J. Exp. Med., 182, 1163(1995);Non-patent literature 7: Nakayama. T., et al., Int. Arch. AllergyImmunol., 124,:38-42 (2001);Non-patent literature 8: J. Exp. Med., 190,783-792, (1999);Non-patent literature 9: Nat. Med., 7:1052-1056 (2001);Non-patent literature 10: Biochem. Biophys. Acta, 280, 626 (1972);Non-patent literature 11: Biochem. Biophys. Acta, 316, 317 (1973);Non-patent literature 12: Biol. Pharm. Bull., 18, 1487 (1995);Non-patent literature 13: J. Exp. Med.,186:677 (1997);Non-patent literature 14: J. Immunol., 166:62 (2001);Non-patent literature 15: J. Exp. Med.,194:1801 (2001); andNon-patent literature 16: Nature, 413:531(2001).

DISCLOSURE OF INVENTION

It is an object of the present invention to provide a drug targeting aregulatory cell in vivo, mainly a drug for immune diseases including butnot limited to allergic diseases and autoimmune diseases.

The present inventors have found that a composition having a regulatorycell ligand such as β-galactosyl ceramide and α-galactosyl ceramidecompounds contained in a liposome has an inducible action ofIL-10-producing T cells and an inhibitory action on IgE antibodyproduction which are not exerted by a solution of these compound aloneand is effective as a preventive or therapeutic agent for the immunediseases such as allergic diseases. The present inventors have furtherfound that a composition having α-galactosyl ceramide contained in aliposome can inhibit differentiation and proliferation of pathogenic Tcells by selectively augmenting immunosuppressive functions of NKT cellsand thus is effective as a preventive or therapeutic agent forautoimmune diseases and graft-versus-host disease, and have completedthe present invention.

That is, the present invention is as follows.

[1] Drugs comprising a liposome containing a regulatory cell ligand, asan active ingredient.

[2] The drugs of [1] wherein the regulatory cell is an NKT cell.

[3] The drugs of [1] or [2] wherein the regulatory cell ligand isβ-galactosyl ceramide substances.

[4] The drugs of [1] or [2] wherein the regulatory cell ligand isα-galactosyl ceramide substances.

[5] The drugs of any of [1] to [4] wherein the liposome further containsCpG oligonucleotide or imiquimod.

[6] The drugs of any of [1] to [5] wherein the liposome further containsone or more selected from the group consisting of allergens,autoantigens and derivatives thereof, which derivatives are antigenshaving one or more T cell epitopes.

[7] The drugs of any of [1] to [6] which is a preventive agent or atherapeutic agent for immune diseases.

[8] The drugs of [7] wherein the immune diseases are allergic diseases.

[9] The drugs of [8] wherein the allergic diseases are atopic bronchialasthma, allergic rhinitis, pollinosis or atopic dermatitis.

[10] The drug of [4] which is a preventive agent or a therapeutic agentfor autoimmune diseases or graft-versus-host disease.

[11] A regulatory cell-inducing agent comprising a liposome containing aregulatory cell ligand, as an active ingredient.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows results of in vitro cytokine production experiments inwhich a Lipo-β composition or other liposome compositions or saline wasadded to a culture system of CD11c⁺ DC from spleen of BALB/c mice. Avertical axis shows concentrations of various cytokines in culturesupernatants after the addition.

FIG. 2 shows results of in vitro cytokine production experiments inwhich the Lipo-β composition or the other liposome compositions orsaline was added to the culture system of CD11c⁺ DC from spleen ofC57BL/6 mice. The vertical axis shows the concentrations of variouscytokines in the culture supernatants after the addition;

FIG. 3 shows results of in vitro cytokine production experiments inwhich the Lipo-β composition or the other liposome compositions orsaline was added to the culture system of CD11c⁺ DC from spleen ofBALB/c mice. The vertical axis shows the concentrations of IL-10 in theculture supernatants after the addition;

FIG. 4 shows the results of measuring the production of DNP-OVA specificantibody in plasma by ELISA. BDF1 mice were administered with Lipo-β orsaline, then immunized with DNP-OVA and alum followed by being boostedwith DNP-OVA alone. ELISA was performed after the primary immunizationand after the boosting.

FIG. 5 shows the results of measuring the concentrations of cytokines inculture supernatants after culturing CD11c⁺ cells obtained from spleenof BALB/c mice 7 days after Lipo-β or saline (negative control) wasadministered and CD4⁺ T cells derived from DO11.10 mice (transgenic micetransfected with OVA specific TCRαβ) in the presence of OVA peptide for4 days.

FIG. 6 shows the results of measuring antibody titers in blood on the14th days after immunizing with DNP-OVA and alum after the cells whichproliferated in the experiments in FIG. 5 were adoptively transferred inBALB/c mice.

FIG. 7 shows the results of measuring the in vitro production ofcytokines. Medium, an aqueous solution of α-galactosyl ceramide(α-GalCer), a liposome composition as the control (Lipo-(-)) or anα-galactosyl ceramide-containing liposome (Lipo-αGC) was added to thecultures of whole spleen cells (upper panels) and the spleen cells towhich anti-CD1d neutralization antibody had been added or in which NKTcells had been deleted (lower panels) in C57BL/6 mice. The horizontalaxis represents the concentration of each cytokine in the culturesupernatant 2 days after the addition.

FIG. 8 shows the results of analyzing the numbers of Vα14-NKT cells inthe spleen by flow cytometry 3 days or 7 days after saline, Lipo-(-) orLipo-αGC was administered to C57BL/6 mice. The horizontal axis and thevertical axis represent fluorescence intensity of FITC-labeled anti-TCRPantibody and PE-labeled CD1d tetramer+ α-GalCer, respectively.

FIG. 9 shows antibody titers of anti-NP-IgE, anti-NP-IgG1 andanti-NP-IgG2a in blood. Saline, α-GalCer, Lipo-(-) or Lipo-αGC wasadministered to C57BL/6 mice (upper panels) or IL-10 gene-deficient mice(lower panels), after 3 days, which were immunized with DNP-OVA andalum, and after 14 days, the titers were measured.

FIG. 10 shows antibody titers of anti-DNP-IgE, anti-DNP-IgG1,anti-DNP-IgG2a, and levels of total IgE, total IgG1 and total IgG2a.Saline, α-GalCer, Lipo-(-) or Lipo-αGC was administered to BDF1 mice,after 3 days (day 0), which were immunized with DNP-OVA and alum, andboosted with DNP-OVA alone on day 55. The titers were measured on days0, 14, 55 and 64.

FIG. 11 shows the results of measuring cell proliferation ability by MTTmethod. Saline, α-GalCer, Lipo-(-) or Lipo-αGC was administered to BDF1mice, after 3 days, which were immunized with DNP-OVA and alum. After 7days, spleen CD4⁺ T cells and radiation-irradiated whole spleen cellsfrom intact BDF1 mice were stimulated with NDP-OVA or PMA/ionomycin.After 48 hours, the cell proliferation ability was measured. In the leftfigure, the horizontal axis and the vertical axis represent theconcentration of DNP-OVA and absorbance at a wavelength of 570 nm,respectively.

FIG. 12 shows the results of analyzing the cells by flow cytometry.Saline, α-GalCer, Lipo-(-) or Lipo-αGC was administered to BALB/c mice.After 3 days, the spleen cells were stained with anti-CD11c antibody andanti-CD45RB antibody.

FIG. 13 shows the number of CD11c^(low)CD45RB^(high) cells and thenumber of CD11c^(high)CD45RB^(low) cells obtained by multiplying a cellnumber ratio obtained in flow cytometry memory analysis in FIG. 11 bythe number of whole spleen cells.

FIG. 14 shows the results of measuring cytokines in culturesupernatants. Lipo-αGC was administered to BALB/c mouse. After 3 days,the CD11c^(low)CD45RB^(high) cells and the CD11c^(high)CD45RB^(low)cells separated from the spleen cells were stimulated with LPS. After 2days, the culture supernatants were analyzed. The horizontal axisrepresents the concentration of the cytokine in the culture supernatant.

FIG. 15 shows the results of measuring the cell proliferation ability byMTT method. The CD11c^(low)CD45RB^(high) cells or theCD11c^(high)CD45RB^(low) cells pulsed with OVA₃₂₃₋₃₃₉ peptide wereco-cultured with CD4⁺ T cells derived from spleen of DO11.10 mouse, andafter 48 hours, the cell proliferation ability was assayed. Thehorizontal axis represents the absorbance at a wavelength of 570 nm.

FIG. 16 shows the results of flow cytometry analysis using anti-CD4antibody, and anti-CD25 antibody, anti-CD28 antibody, anti-CD152antibody or anti-ICOS antibody. Cells proliferated by co-culturing theCD11c^(low)CD45RB^(high) cells or the CD11c^(high)CD45RB^(low) cellspulsed with OVA₃₂₃₋₃₃₉ peptide with the CD4⁺ T cells derived from spleenof DO11.10 mouse were analyzed.

FIG. 17 shows the results of analyzing intracellular cytokine expressionby flow cytometry. The cells proliferated by co-culturing theCD11c^(low)CD45RB^(high) cells or the CD11c^(high)CD45RB^(low) cellspulsed with OVA₃₂₃₋₃₃₉ peptide with the CD4⁺ T cells derived from spleenof DO11.10 mouse were stimulated with PMA and ionomycin, and analyzed byflow cytometry. The upper panels represent intracellular stainingpatterns by the corresponding isotype control antibody. The lower panelsrepresent the intracellular staining patterns by the cytokine-specificantibody.

FIG. 18 shows the results of analyzing the intracellular cytokineexpression by flow cytometry. The CD4⁺ T cells from the spleen of BDF1mouse administered with Lipo-αGC or Lipo-αGC+OVA were in vivo culturedwith radiation irradiated spleen cells from the same BDF1 in thepresence of OVA, and after 6 days, the cultured cells were stimulatedwith PMA and ionomycin. The upper panels represent the intracellularstaining patterns of CD4⁺ T cells from the spleen of the mouseadministered with Lipo-αGC, and the lower panels represent theintracellular staining pattern of CD4⁺ T cells from the spleen of themouse administered with Lipo-αGC+OVA.

FIG. 19 shows antibody titers of anti-DNP-IgE, anti-DNP-IgG1,anti-DNP-IgG2a (upper panels), and levels of total IgE, total IgG1 andtotal IgG2a (lower panels) in blood. BDF1 mice were immunized withDNP-OVA and alum, on days 21, 28 and 35, a liposome alone (vehicle),Lipo-αGC or Lipo-αGC+OVA was administered, and then on day 42, the micewere boosted with DNP-OVA antigen alone. On day 48, the antibodies wereassayed. * p<0.05, ** p<0.005, *** p<0.001

FIG. 20 is a view showing the concentrations of anti-DNP IgE, IgG1 andIgG2a in blood from mice administered with α-GC liposome or α-GC-OVAliposome, which had been sensitized with DNP-OVA or DNP-KLH.

FIG. 21 is a view showing the concentrations of anti-OVA IgE in bloodfrom mice administered with α-GC liposome or α-GC-OVA liposome or amixed solution of α-GC liposome and OVA, which had been sensitized withDNP-OVA.

MODES FOR CARRYING OUT THE INVENTION

Herein, “regulatory cells” includes but is not limited to NKT cells(natural killer T cells), IL-10-producing Trl cells and dendritic cells(DC), and among them, the NKT cell is particularly preferable.

A “regulatory cell ligand” is not particularly limited as long as theligand is bound to a cell surface receptor on the above regulatory cellto facilitate differentiation/proliferation or activation of theregulatory cell, and includes the followings. But, the regulatory cellligand is not limited thereto.

(i) Galactosyl ceramides such as α-galactosyl ceramide and β-galactosylceramide substance which are the ligands of the NKT cells.

(ii) Vitamin D3, dexamethasone, TGF-β and IL-10 which serve for thedifferentiation/proliferation of regulatory dendritic cells (DC).

(iii) Substances which induce the expression of IL-10 or FoxP3 whichserves for the differentiation/proliferation of regulatory T cells.

(iv) IGb3 (Isoglobo-glycosphingolipid) present in vivo.

A “regulatory cell-inducing agent” of the present invention refers to amedicament which induces the differentiation/proliferation or theactivation of the regulatory cells. The facilitation of thedifferentiation/proliferation or the activation of the regulatory cellscan be identified, for instance, as described in Examples, by usingspleen CD11c⁺ DC and measuring the proliferation of the NKT cells or theIL-10-producing Tr1 cells contained therein, or quantifying cytokines(IFN-γ, IL-10, IL-4) produced by NKT cells and the IL-10-producing Tr1cells.

As a “liposome containing the regulatory cell ligand” of the presentinvention, those inducing the NKT cells and the IL-10 producing Tr1cells which are the regulatory cells, further having an activity tosuppress the activation of helper T cells and having an inhibitoryaction on the production of IgE antibody released from B cells arepreferable. Specifically, those containing the “regulatory cell ligand”as the above in the liposome are preferable, and among them acomposition including α-galactosyl ceramide or β-galactosyl ceramide ina lipid double membrane of the liposome is preferable. The “liposomecontaining the regulatory cell ligand” of the present invention maycontain two or more “regulatory cell ligands”.

The “liposome containing the regulatory cell ligand” of the presentinvention may further contain TLRs (Toll-like receptor) family ligandsin addition to the regulatory cell ligand. The addition of the TLRsfamily ligands can increase the production of cytokines which regulatethe action of the “regulatory cells” and further enhances the effect.The TLRs family ligands include CpG oligonucleotide (CpGODN) andimiquimod (1-(2-methylproryl)-1H-imidazo[4,5-c] quinolin-4-amine).

The “liposome containing the regulatory cell ligand” may also containone or more selected from the group consisting of allergens,autoantigens and derivatives thereof, which derivatives are antigenshaving one or more T cell epitopes.

The allergen is not particularly limited as long as it is a factor whichthe living body is exposed to, the living body ingests or is applied tothe living body and can cause the allergy. Such an allergen includespollens (e.g., Japanese cedar, Japanese cypress, ragweed, rice plant,white birch, cocksfoot, felon herb), foods (e.g., cow milk, buckwheat,egg, peanut, wheat, soy bean, fish, fruit, and processed productsthereof), organisms other than human beings or things derived therefrom(e.g., mites, fungi, body hairs from animals and birds, bee toxin),medicaments (e.g., penicillin based antibiotics, sulfa drugs, barbituricacid derivatives), medical items (e.g., natural rubber gloves),livingwares (e.g., metals of accessories), and factors capable ofcausing the allergy included in other substances or compositions(latex). Specifically the allergen includes OVA (ovalbumin), ragweedantigen Amb a1 and cedar pollen antigens such as Cryj1 and Cryj2.

The drug of the present invention is useful as the therapeutic agentspecific for the allergic disease caused by an allergen or derivativethereof when the drug contains the allergen or derivative thereof. Thepresent inventors have found that since the liposome containing theregulatory cell ligand and an allergen specifically inhibits theproduction of IgE caused by the allergen, the allergic disease caused bythe allergen can be treated with such a liposome. The allergic diseasescapable of being specifically treated with the drug of the presentinvention include atopic bronchial asthma, atopic dermatitis, allergicrhinitis (e.g., pollen disease), allergic conjunctivitis, food allergyand medicament allergy.

An autoantigen is not particularly limited as long as it is the antigenwhich can be targeted by immune cells in autoimmune diseases. Theautoantigen includes, for example, collagen, nucleic acids (rheumatoidarthritis, systemic lupus erythematosus), myelin basic protein (MBP)(multiple sclerosis), thyroglobulin (thyroid autoimmune disease) andgraft allogenic antigen (graft versus host disease).

The drug of the present invention is useful as the therapeutic agent forthe autoimmune disease when the drug contains the liposome containingone or more selected from the group consisting of autoantigens andderivatives thereof, which derivatives are antigens having one or more Tcell epitopes. The present inventors have found that the liposomecontaining the regulatory cell ligand and an allergen can specificallytreat the allergic disease caused by the allergen, and thus haveconceived that the autoimmune disease caused by an autoantigen can besimilarly treated specifically by utilizing a medicament deliveryvehicle containing the autoantigen in place of the allergen. Such anautoimmune disease includes, for example, those described above.

The present invention provides the liposome in which the regulatory cellligand as the above, preferably a lipid-soluble compound such asgalactosyl ceramide has been incorporated as a water solublemacromolecular substance. Herein, one having a vesicular structure wherea micelle (water soluble particle obtained by aggregating amphipathicmolecules including a hydrophilic region and a hydrophobic region) hasbeen closed is referred to as the liposome. A liposome component may beany ones as long as it is the amphipathic molecule which can form themicelle by known methods, and preferably includes lipids. The lipid inthe present invention includes phospholipids such asdipalmitoylphosphatidylcholine (DPPC), dioleylphosphatidylcholine (DOPC)and dioleylphosphatidyl ethanolamine (DOPE), sphingoglycolipid andglyceroglycolipid. These are used for making the liposome, alone or incombination of two or more or in combination with a lipid derivativewhere a non-polar substance such as cholesterol or a water solublepolymer such as polyethylene glycol has been bound to the lipid.

The liposome can be prepared in accordance with publicly known methods.For example, the methods described in Liposome Technology, vol. 1,2^(nd) edition (by Gregory Gregoriadis (CRC Press, Boca Raton, AnnArbor, London, Tokyo), Chapter 4, pp67-80, Chapter 10, pp167-184 andChapter 17, pp261-276 (1993)) can be used. More specifically, themethods include, but are not limited to, a sonication method, an ethanolinjection method, a French press method, an ether injection method, acholic acid method, a calcium fusion method, a lyophilization method anda reverse phase evaporation method. A size of the liposome of thepresent invention is not particularly limited, and typically ispreferably 100 to 200 nm and more preferably 100 to 150 nm in average.The structure of the liposome is not particularly limited, and may beany liposome such as unilamella and multilamella. As a solutionencapsulated inside the liposome, it is possible to use buffer andsaline and others in addition to water. It is also possible to add awater soluble organic solvent (e.g., glycerine) in an appropriate amountthereto and use it.

The liposome used for the drug of the present invention may be thoseobtained by modifying the liposome surface for targeting the “liposomecontaining the regulatory cell ligand” to a target site. The target siteincludes, for example, liver, spleen, lymph node, bone marrow, lung,eye, skin and nose.

The substance which modifies the liposome surface includes low molecularcompounds, high molecular compounds, nucleic acids, peptides, proteinsand sugar chains. The high molecular compound includes polyethyleneglycol (see U.S. Pat. No. 2,948,246). The nucleic acid includes, forexample, single strand RNA and single strand DNA which recognize TLR-7or TLR-9 of the Toll-like receptor in the target cell, and derivativesof these nucleic acids. The protein includes, for example, antibodiesand receptors which recognize the molecules expressed specifically onthe surface of the target cells such as dendritic cells (DC) which areantigen presenting cells or precursor cells thereof. The modificationwith the sugar chain includes the modification with mannose bound lipidwhich can be bound to a mannose receptor expressed on the surface of DC(e.g., see Copland, M. J., et al., (2003)Liposome delivery of antigen tohuman dendritic cells, Vaccine, 21:883-890).

Inclusion of the ligand into the liposome can be performed by ordinarymethods. For example, as shown in Examples, the liposome containing theregulatory cell ligand can be obtained by separately dissolving theliposome component and the ligand in the organic solvent, mixing theseand adding water. But the method for producing the liposome containingthe regulatory cell ligand is not limited to the above.

The “liposome containing the regulatory cell ligand” can be used as theactive ingredient of the drug.

That is, the drug of the present invention is effective as thepreventive agent or the therapeutic agent for the allergic diseasescaused by IgE antibody because the “liposome containing the regulatorycell ligand” induces the NKT cells or the IL-10-producing Tr1 cellswhich are the regulatory cells, has the activity to suppress theactivation of the helper T cells and has the inhibitory action on theproduction of the IgE antibody released from B cells. The IgE antibodyis particularly deeply associated with the allergic diseases, and thusby suppressing the production (secretion) thereof, it is possible toobtain the preventive or therapeutic effect on the type I allergicdiseases. The allergic diseases associated with the IgE antibody includeatopic bronchial asthma, atopic dermatitis and nasal allergy such asallergic rhinitis and pollinosis. In the present invention, theprevention of the allergic disease encompasses not only making mammaliananimals including human beings who have not had the allergic diseasefree from the disease but also making the patients (mammalian animalsincluding human beings) with allergic disease who have not had thesymptom temporarily free from the symptom.

The drug of the present invention is also effective as the preventiveagent or the therapeutic agent for the disease such as fulminanthepatitis because the “liposome containing the regulatory cell ligand”has the action to suppress the activation of the T cells.

The drug containing the liposome containing α-galactosyl ceramide as theactive ingredient is effective as the drug having an immunosuppressiveability because the liposome containing α-galactosyl ceramide has theeffect to selectively augment the immunosuppressive function of the NKTcells. Specifically, the drug is effective as the drug for autoimmunediseases such as rheumatoid, multiple sclerosis, systemic lupuserythematosus and collagen disease and the drug for rejection upontransplantation such as GVHD.

α-Galactosyl ceramide is not particularly limited as long as it is boundto the surface receptor of the NKT cell to selectively augment theimmunosuppressive function of the NKT cell, but is preferably one boundto the receptor composed of Vα24JαQ in human or Vα14Jα281 in mouse. Themolecular weight thereof is preferably 400 to 2,000.

Meanwhile, the molecular weight of β-galactosyl ceramide used for thepresent invention is preferably 400 to 2,000.

As another embodiment of the present invention, the drug comprising theliposome containing imiquimod, as the active ingredient is provided. Bycontaining imiquimod in the liposome, the production amounts of IL-10and IFNα are enhanced thereby activating the NKT cells compared with thecase of using imiquimod alone. Therefore, the drug comprising theliposome containing imiquimod as the active ingredient is useful for theprevention or the treatment of the allergic diseases as described above.

For an administration route of the drug of the present invention, thedrug can be administered both orally or parenterally, and the route isoptionally selected by a physician. The “liposome containing theregulatory cell ligand” as the active ingredient can be administeredalone or in combination with a carrier usually used.

When the drug of the present invention is orally administered, a form ofthe drug includes solid formulations such as tablets, coated tablets,powdered agents, granules, capsules and pills, liquid formulations suchas liquid agents (e.g., eye drops, nose drops), suspension, emulsion andsyrup, inhales such as aerosol agents, atomizers and nebulizers, andliposome inclusion agents.

When the drug of the present invention is parenterally administered, theform of the drug includes injectable agents (liquid agents, suspensions)used for intravenous injection, subcutaneous injection, intraperitonealinjection, intramuscular injection and intraperitoneal injection, liquidagents, suspensions, emulsions and dripping agents.

When the drug of the present invention is the liquid formulation, thedrug may be stored in a frozen state or lyophilized by removing thewater. Injectable distilled water is added to the lyophilizedformulation to re-dissolve the formulation before use.

As pharmaceutically acceptable carriers utilized for the drug of thepresent invention, it is possible to exemplify binders, disintegrants,surfactants, absorption accelerators, moisture retention agents,absorbers, lubricants, fillers, extenders, moisture imparting agents,preservatives, stabilizers, emulsifiers, solubilizing agents, saltswhich control osmotic pressure, diluting agents such as buffers andexcipients usually used depending on the use form of the formulation.These are optionally selected and used depending on the unit dosage ofthe resulting formulation.

Additionally, coloring agents, preserving agents, perfumes, flavors andsweeteners, and other pharmaceutical articles can be contained in thedrug of the present invention as needed to prepare as the agent.

An effective amount of the “liposome containing the regulatory cellligand” can be easily determined by those skilled in the art withreference to the conventional art, and is, for example, about 0.1 to 100mg per 1 kg of body weight and preferably about 1 to 10 mg, and this canbe administered by dividing into 1 to 3 times daily. It is preferable tooptionally regulate the dosage depending on the form of eachformulation, a gender, an age and a disease condition of the patient.

EXAMPLES

The present invention will be described with reference to the followingExamples, but the present invention is not limited to these Examples,and it goes without saying that usual changes in the art of the presentinvention can be made.

Example 1 <Preparation of Ligand-Containing Liposome and Measurement ofActivity> 1. Preparation of β-Galactosyl Ceramide-Containing Liposome(Lipo-β)

L-α-Phosphatidylethanolamine, dioleoyl (DOPE; Wako Pure Chemical#166-16183, 0.77 mg), 0.83 mg of cholesteryl313-N-(dimethylaminoethyl)carbonate hydrochloride (DC-Chol;SIGMA-Aldrich) and 0.029 mg of1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (AVANTI POLAR-LIPIDS, INC. #i88653) were dissolved in 250μL of chloroform/methanol (1:1) solvent. β-Galactosyl ceramide (ceramide≈-D-galactoside; Sigma-Aldrich #C4905, 0.16 mg) was separately dissolvedin 250 μL of chloroform/methanol (1:1) solvent. Both were mixed andevaporated using an evaporator, and subsequently dried overnight in adesiccator under vacuum. Then, 800 μL of water was added, the mixturewas treated with a sonicator for one minute, then particle sizes wereselected by filtration with pressure using an extruder (AVESTIN;LiposoFast-Basic), and the particles were sterilized with a membranehaving a pore size of 0.22 μm. This liposome composition (Lipo-β) wasadjusted to a final concentration of 200 μL/mL. By the same method, aliposome composition containing no β-galactosyl ceramide (Lipo-0) wasprepared. An eluted product collected through a salting out columnNAP-10 after mixing oligonucleotide CpGODN (1668) (supplied from SIGMAGENOSIS) with Lipo-β at a weight ratio of 5:1 was rendered Lipo-β-CpG.

2. Preparation of Imiquimod-Containing Liposome

L-α-Phosphatidylethanolamine, dioleoyl (DOPE; Wako Pure Chemical#166-16183, 0.77 mg), 0.83 mg of cholesteryl3β-N-(dimethylaminoethyl)carbonate hydrochloride (DC-Chol;SIGMA-Aldrich) and 0.029 mg of1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-[Methoxy(polyethyleneglycol)-2000] (AVANTI POLAR-LIPIDS, INC. #188653) were dissolved in 250μL of chloroform/methanol (1:1) solvent. Imiquimod (Sequoia ResearchProducts Ltd; SRP0058i, 0.16 mg) was separately dissolved in 250 μL ofchloroform/methanol (1:1) solvent. Both were mixed and evaporated usingan evaporator, and subsequently dried overnight in a desiccator undervacuum. Then, 800 μL of water was added, the mixture was treated withthe sonicator for one minute, then particle sizes were selected byfiltration with pressure using the extruder (AVESTIN; LiposoFast-Basic),and the particles were sterilized with the membrane having a pore sizeof 0.22 μm. This liposome composition (Lipo-Imq) was adjusted to a finalconcentration of 200 μL/mL. By the same method as in the abovecomposition, a liposome composition (Lipo-Imq-βGC) containing ceramideβ-D-galactoside (Sigma-Aldrich #C4905) was prepared. An eluted productcollected through the salting out column NAP-10 after mixingoligonucleotide CpGODN (1668) (supplied from SIGMA GENOSIS) withLipo-Imq at a weight ratio of 5:1 was rendered Lipo-Imq-CpG.

3. Measurement of In Vitro Activity of Ligand-Containing Liposome forDendritic Cells (DC)

Collagenase D (1 mg/mL, Roche) was injected into spleen from BALB/c orC57BL/6 mouse, which was then incubated in a CO₂ incubator for 45minutes. Subsequently, cells were collected from the spleen, suspendedin 3 mL of HistoDenz (14.1%, SIGMA), and then X-VIVO 15 (Takara Bio)containing 50 μM 2-mercaptoethanol (2ME) was overlaid thereon. Aftercentrifuging at 1,500 rpm for 5 minutes, the cells in an intermediatelayer were collected and incubated in X-VIVO 15 medium containing 50 μM2ME, 0.5% fetal calf serum and 20 ng/mL rmGM-CSF (Pharmingen) in the CO₂incubator for one and a half hours. After pipetting gently, thesuspended cells were removed, the X-VIVO 15 medium containing 50 μM 2ME,0.5% fetal calf serum and 20 ng/mL rmGM-CSF (Pharmingen) was added, andthe cells were incubated in the CO₂ incubator for 18 hours. Thesuspended cells were collected, and the cells bound to anti-CD11cantibody-magnetic microbeads (Miltenyi) were collected to render spleenCD11c⁺ DC. The CD11c⁺ DC at 1×10⁴ cells were suspended in 200 μL of RPMImedium containing 10% fetal calf serum in a 96-well round bottommicrotiter plate, the liposome composition at a final concentration of 1μg/mL was added thereto, and the plate was incubated in the incubatorcontaining 5% CO² at 37° C. After 48 hours, culture supernatants werecollected, and levels of IFN-α, IL-10 and IL-12 were measured by ELISA(FIGS. 1 and 2). The levels of IL-10 and IFN-α were high whereas thelevels of IL-12 were low in Lipo-β and Lipo-Imq groups. Conversely, inLipo-β-CpG and Lipo-Imq-CpG groups, the levels of IL-10 and IFNα werelow whereas the levels of IL-12 were high. Meanwhile, in thenon-addition group (control), Lipo-0 and the β-galactosyl ceramidesolution (β-GalCer) groups, the production of all cytokines was notdetected or was very low. In the same evaluation method, the productionlevels of IL-10 in CD11c⁺ DC by Lipo-Imq-βGC were measured. As a result,it was found that Lipo-Imq-βGC induced IL-10 production at much higherlevels than Lipo-β alone or Lipo-Imq alone (FIG. 3).

Example 2 <Inhibitory Effect of Lipo-β on In Vivo Production of IgEAntibody>

Lipo-β (2 μg/mouse) was intraperitoneally injected in BDF1 mice (5mice/group), after 7 days (day 0), which were primarily immunized with0.1 μg of DNP-OVA (Cosmobio) and 10 mg of alum. On the 14th day afterthe primary immunization, blood was collected from orbital venousplexus, and antibody titers of ant-DNP-IgG1, anti-DNP-IgE andanti-DNP-IgG2a in plasma were measured by ELISA (14th day in FIG. 4).The mice were boosted with DNP-OVA alone on the 35th day after theprimary immunization, and 7 days thereafter, the antibody titers ofanti-DNP-IgG1 and anti-DNP-IgE in the plasma from the blood collectedfrom the orbital venous plexus were measured by ELISA (42nd day in FIG.4). In the Lipo-β group, on the day 14, the production of IgG antibodyand IgE antibody tended to be already inhibited, and on the day 42, theincrease of IgG antibody and IgE antibody was completely inhibited afterthe boost immunization.

Example 3

<Induction of regulatory T cells by dendritic cells (DC) derived frommice administered with Lipo-β>1. Evaluation of in vitro activation ability of T cells

Lipo-β or saline (2 μL/mouse) was intraperitoneally administered toBALB/c mice, and after 7 days, the spleen was removed. Collagenase D (1mg/mL, Roche) was injected into the spleen, which was then incubated inthe CO₂ incubator for 45 minutes. Subsequently, cells were collectedfrom the spleen, suspended in 3 mL of HistoDenz (14.1%, SIGMA), and thenX-VIVO 15 containing 50 μM 2-mercaptoethanol (2ME) was overlaid thereon.After centrifuging at 1,500 rpm for 5 minutes, the cells in theintermediate layer were collected and incubated in the X-VIVO 15 mediumcontaining 50 μM 2ME, 0.5% fetal calf serum and 20 ng/mL rmGM-CSF(PharMingen) in the CO₂ incubator for one and a half hours. Afterpipetting gently, the suspended cells were removed, the X-VIVO 15 mediumcontaining 50 μM 2ME, 0.5% fetal calf serum and 20 ng/mL rmGM-CSF(PharMingen) was added, and the cells were incubated in the CO₂incubator for 18 hours. The suspended cells were collected, and thecells bound to anti-CD11c antibody-magnetic microbeads (Miltenyi) werecollected to render spleen CD11c⁺ DC. CD4⁺ T cells were collected fromOVA specific TCRaf transgenic mouse DO11.10 (given by Dr. ToshinoriNakayama, Graduate School of Medicine, Chiba University; Science, 1990,vol. 250, p1720) using antibody-magnetic microbeads (Miltenyi).Subsequently, CD11c⁺ DC at 2×10⁴ cells and CD4⁺ T cells at 1×10⁵ cellswere cultured in the presence of the OVA peptide in the CO₂ incubatorfor 4 days, then the culture supernatant was collected, and the levelsof IFNγ, IL-4 and IL-10 were measured by ELISA (FIG. 5). As a result,when DC from the spleen of the mouse administered with Lipo-β were usedand when DC from the spleen of the mouse administered with saline(normal) were used, no difference was observed in the levels of IL-4 andIFN-γ production. However, the production of IL-10 was observed only atOVA peptide concentrations of 3 nM and 30 nM when DC from the spleen ofthe mouse administered with Lipo-β were used. Simultaneously, theproliferation of the regulatory cells was also identified.

2. Evaluation of Inhibitory Effect on In Vivo IgE Antibody Production byAdoptive Transfer Method

DO11.10-CD4⁺ T cells which had proliferated at OVA peptideconcentrations of 3 nM or 30 nM and DC from the spleen of the mouseadministered with Lipo-β in the above 1. in vitro experiment werecollected, and 1×10⁶ thereof were intraperitoneally transferred intoBALB/c mice (3 mice/group). After one hour, the mice were primarilyimmunized with DNP-OVA (10 μg) and alum (10 mg), and on the 14th day,the blood was collected from the orbital venous plexus. The antibodytiters of anti-DNP-IgG1, anti-DNP-IgE and anti-DNP-IgG2a in the plasmawere measured by ELISA (FIG. 6). As a result, the production of IgEantibody was completely inhibited in the mice in which DO11.10-CD4⁺ Tcells grown by the stimulation of OVA peptide at 3 nM had beenadoptively transferred. Meanwhile, the inhibitory effect on the IgEantibody production was low in the mice in which DO11.10-CD4⁺ T cellsgrown by the stimulation of OVA peptide at 30 nM had been adoptivelytransferred. The inhibition of IgG1 and IgG2a antibody production wasnot remarkable in both groups.

Example 4 <Preparation of Ligand-Containing Liposome and Measurement ofActivity> 1. Preparation of α-Galactosyl Ceramide-Containing Liposome

L-α-Phosphatidylethanolamine, dioleoyl (DOPE; Wako Pure Chemical#166-16183, 0.77 mg) and 0.83 mg of cholesteryl3β-N-(dimethylaminoethyl)carbonate hydrochloride (DC-Chol; Sigma-Aldrich#C2832) were dissolved in 250 μL of chloroform/methanol (1:1) solvent.α-Galactosyl ceramide (0.16 mg, supplied from RIKEN Research Center forAllergy and Immunology; KRN7000, see International Publication PamphletWO98/44928) was separately dissolved in 250 μL of chloroform/methanol(1:1) solvent. Both were mixed and evaporated using the evaporator, andsubsequently dried overnight in the desiccator under vacuum. Then, 800μL of water was added, the mixture was treated with the ultrasonicpulverizer for one minute, and passed through a membrane having a poresize of 0.22 μm for sterilization. This liposome composition (Lipo-αGC)was adjusted to a final concentration of 200 μL/mL. By the same method,a liposome composition containing no α-galactosyl ceramide (Lipo-(-))for the control was prepared.

2. Measurement of Cytokine Production by Lipo-αGC

Spleen whole cells at 2×10⁵ from C57BL/6 mouse were suspended in 200 μLof 10% fetal calf serum (FCS)-containing RPMI medium to which 100 ng/mLLipo-(-), Lipo-αGC or α-galactosyl ceramide aqueous solution (α-GalCer)had been added, then the cell suspension was added to a 96-well U bottomculture plate, and cultured in the incubator containing 5% CO₂ at 37° C.for 2 days. The levels of IFN-γ, IL-4 and IL-10 produced in the culturesupernatant were measured by ELISA (FIG. 7 upper panels). The levels ofIFN-γ and IL-4 were equivalent in Lipo-αGC group and αGalCer group, butthe level of IL-10 in the Lipo-α group was 5 times higher than that inthe α-GalCer group. When the same experiments were performed in thepresence of anti-CD1d neutralization antibody (1B1, BD BiosciencePharMingen) at a final concentration of 10 μg/mL or using spleen wholecells from Vα14-NKT cell-deficient mouse (C57BL/6 background), IFN-γ,IL-4 and IL-10 in the culture supernatant were not detected (FIG. 7,lower panels).

3. Evaluation of Vα14-NKT Cell Proliferation Ability by Lipo-αGC

Lipo-αGC (2 μg/mouse), or Lipo-(-) or saline as the control wasintraperitoneally administered to C57BL/6 mice. On the 3rd day (day 3)and the 7th day (day 7), the spleen cells were stained with αGalCer/CD1dtetramer and anti-TCRβ antibody, and the number of double positive cells(Vα14-NKT cells) was analyzed by flow cytometry. As a result, it wasidentified that the number of the Vα14-NKT cells in the spleen of themouse 3 days after the administration of Lipo-α was increased 2 times ormore compared with that from the spleen administered with saline, but onday 7, the number was reversely reduced compared with that from thecontrol mice (FIG. 8).

Example 5 <Inhibitory Effect of Lipo-αGC on In Vivo AntibodyProduction> 1. Activity Evaluation in In Vivo Antibody Production SystemUsing C57BL/6 and IL-10-Deficient Mice

Saline, α-GalCer, Lipo-(-) or Lipo-αGC (2 μg/mouse) wasintraperitoneally administered in C57BL/6 mice (5 mice/group), after 3days, which were primarily immunized with DNP-OVA and alum. On the 14thday after the primary immunization, the blood was collected from theorbital venous plexus, and antibody titers of ant-DNP-IgG1, anti-DNP-IgEand anti-DNP-IgG2a in the plasma were measured by ELISA. As a result,the inhibitory effect on the antibody production in the Lipo-αGC grouptended to be higher than in the α-GalCer group for all isotypes examined(FIG. 9 upper panels). The same experiment was performed using theIL-10-deficient mice with C57BL/6 background. As a result, no inhibitoryeffect on the antibody production was observed (FIG. 9 lower panels).

2. Activity Evaluation in In Vivo Antibody Production System Using BDF1Mice

Saline, α-GalCer, Lipo-(-) or Lipo-αGC (2 μg/mouse) wasintraperitoneally administered in BDF1 mice (C57BL/6×DBA/2F1) (5mice/group), after 3 days (day 0), which were primarily immunized withDNP-OVA and alum, and further the mice was boosted with DNP-OVA alone onthe 55th day (day 55) after the primary immunization. On days 0, 14, 55and 64, the blood was collected from the orbital venous plexus, andantibody titers of ant-DNP-IgE, anti-DNP-IgG1, anti-DNP-IgG2a, and thelevels of total IgE, total IgG1 and total IgG2a in the plasma weremeasured by ELISA. As a result, it was identified that the increase ofantibody titers of all isotype anti-DNP and the production of total IgEwere nearly completely inhibited in the Lipo-αGC group (FIG. 10).Meanwhile, the changes of total IgG1 and total IgG2a were nearlyequivalent in the Lipo-αGC group and the α-GalCer group or Lipo-(-)group (FIG. 10).

3. Evaluation of T Cell Activation Ability Using BDF1 Mice

Saline, α-GalCer, Lipo-(-) or Lipo-αGC (2 μg/mouse) wasintraperitoneally administered in BDF1 mice, after 3 days, which wereprimarily immunized with DNP-OVA and alum. After 7 days, the spleen wasremoved, and CD4⁺ T cells were prepared using magnetic microbeads(Miltenyi). Subsequently, antigen presenting cells were prepared byirradiating spleen whole cells from the normal BDF1 mouse with radiationof 20 Gy. The CD4⁺ T cells at 2×10⁵ and the antigen presenting cells at2×10⁵ pulsed with DNP-OVA suspended in 200 μL of the medium were placedin one well of the 96-well U bottom culture plate, and cultured in theincubator containing 5% CO₂ at 37° C. After 48 hours, cell proliferationwas assayed by MTT method (Promega #G4000). As a results, the CD4⁺ Tcells derived from the spleen of the mouse administered with Lipo-αGCdid not proliferate in response to DNP-OVA at all concentrationsexamined, while other CD4⁺ T cells highly proliferated in order ofα-GalCer, saline and Lipo-(-) (FIG. 11 left panel). On the other hand,when the CD4⁺ T cells at 2×10⁵ were stimulated antigen-non-specificallywith 50 ng/mL of phorbol 12-miristate 13-acetate (PMA; Sigma-Aldrich#P-1585) and 500 nM ionomycin (Sigma-Aldrich, #I-0634) in the CO₂incubator containing 5% CO₂ at 37° C. for 48 hours, the CD4⁺ T cellsderived from the mouse administered with Lipo-αGC exhibited lower butsignificant proliferative response compared with other CD4⁺ T cells(FIG. 11, right panel).

4. Analysis of Dendritic Cells (DC) in Spleen of Mice Administered withLipo-αGC

4-1. Analysis Using Flow Cytometry

Saline, α-GalCer, Lipo-(-) or Lipo-αGC (2 μg/mouse) wasintraperitoneally administered in BALB/c mice, and after 3 days, thespleen was removed. Collagenase D (1 mg/mL, Roche) was injected into thespleen, which was then incubated in the CO₂ incubator for 45 minutes.Subsequently, cells were collected from the spleen, suspended in 3 mL ofHistoDenz (14.1%, SIGMA-Aldrich), and then the X-VIVO 15 medium (CAMBREXBio Science Walkerville, Inc.) containing 50 μM 2-mercaptoethanol (2ME)was overlaid thereon. After centrifuging at 1,500 rpm for 5 minutes, thecells in the intermediate layer were collected. The cells were washedwith the X-VIVO 15 medium containing 50 μm 2ME and 10% FCS, andsuspended in phosphate buffered saline (PBS) containing 0.5% FCS.Biotinylated anti-CD3, -CD11b, -CD19, -CD49b, -Gr-1, -TER-119 and -B220antibodies (all from BD Bioscience Pharmingen) were added to the cellsuspension. The cells were incubated at 10° C. for 20 minutes, thenwashed once with PBS containing 0.5% FCS, and subsequently streptoavidin(SA)-conjugated magnetic beads (Miltenyi) were added thereto. The cellswere incubated at 10° C. for 15 minutes, subsequently washed twice withPBS containing 0.5% FCS, and then magnetic microbead-negative cells werecollected using a microbead separation column and a magnet (Miltenyi).The resulting cells were stained with PE-labeled anti-CD11c antibody (BDBioscience Pharmingen) and APC-labeled anti-CD45RB antibody (BDBioscience Pharmingen), and analyzed by flow cytometry. As a result, inthe cells derived from the spleen of the mouse administered withLipo-αGC, the ratio of CD45RB^(high)CD11c^(low) cells was higher thanthe ratio of CD45RB^(low)CD11c^(high) cells, while the ratio wasreversed in the cells derived from the mice administered with saline,Lipo-(-) or α-GalCer (FIG. 12). The ratios were further compared interms of cell number in the spleen. As a result, it was demonstratedthat the number of the CD45RB^(high)CD11c^(low) cells in the spleen ofthe mouse administered with Lipo-αGC increased about 3 times over thenumber of the corresponding cells in the spleen of the mouseadministered with α-GalCer whereas conversely the number of theCD45RB^(low)CD11c^(high) cells increased in the mouse administered withα-GalCer more than in the mouse administered with Lipo-αGC (FIG. 13).

The CD45RB^(high)CD11c^(low) cell is the cell group reported as acontrollable dendritic cell and has the immunosuppressive function.Conversely, the CD45RB^(low)CD11c^(high) cell is the dendritic cellwhich activates the T cell and has the immunostimulatory function. Thus,it was speculated that the immunosuppressive function of the NKT cellswas brought by the increase in the number of theCD45RB^(high)CD11c^(low) cells.

4-2. Evaluation of Cytokine Production Ability

The CD45RB^(high)CD11c^(low) cell population and theCD45RB^(low)CD11c^(high) cell population separated by the methoddescribed above were collected separately using the flow cytometry (FACSVantage SE, BD Bioscience), and the cells at 1×10⁵/200 μL of the mediumwere added into one well in the 96-well U bottom culture plate. Thecells were cultured in the presence or absence of lipopolysaccharide(LPS; T3382, Sigma-Aldrich) at a final concentration of 1 μg/ml for 2days. The levels of the cytokines IL-10 and IL-12 in the culturesupernatant were measured by ELISA. As a result, IL-10 was detected andIL-12 was not detected in the culture supernatant of theCD45RB^(high)CD11c^(low) cells stimulated with LPS whereas IL-12 wasdetected and IL-10 was not detected in the culture supernatants of theCD45RB^(low)CD11c^(high) cells regardless of the presence or absence ofLPS (FIG. 14).

4-3. Evaluation of T Cell Activation Ability

The CD45RB^(high)CD11c^(low) cells or the CD45RB^(low)CD11c^(high) cellswhich are separated by the method described above 2. were added into onewell of the 96-well U bottom culture plate at 1×10⁴ cells/200 μL of themedium. The CD4⁺ T cells purified from the spleen of DO11.10 by themagnetic microbeads (Miltenyi) were added at 4×10⁶ cells/200 μL of themedium thereto. The cells were cultured in the presence or absence ofthe OVA₃₂₃₋₃₃₉ peptide at a final concentration of 600 nM in theincubator containing 5% CO₂ at 37° C. After 48 hours, the proliferativeresponse was assayed by MTT method (Promega #G4000). As a result, theCD4⁺ T cells stimulated with the CD45RB^(high)CD11c^(low) cells and theOVA peptide exhibited the slightly inferior but significantproliferative response compared with the proliferative response inducedby the CD45RB^(low)CD11c^(high) cells (FIG. 15). The CD4⁺ T cells grownby the stimulation with the CD45RB^(high)CD11c^(low) cells and the OVApeptide for 7 days were collected, and cultured with theCD45RB^(high)CD11c^(low) cells or the CD45RB^(low)CD11c^(high) cellsnewly separated/collected in the presence of OVA peptide for 7 days.This culture was performed once more, and on the 5th day, the cells inthe culture were analyzed by flow cytometry. As a result, it wasidentified that the grown cell group was a nearly homogenous cellpopulation with CD4⁺, CD25⁺, CD28⁺, CD152⁻ and ICOS⁺ (FIG. 16).Subsequently, these cells at 5×10⁵ were cultured in the presence of PMAat a final concentration of 50 ng/mL, 500 nM ionomycin and 2 μM Monensin(Sigma-Aldrich #M-5273) in the incubator containing 5% CO₂ at 37° C. for4 hours. The cells were collected, suspended in 100 μL of a BDCytofix/Cytoperm solution (BD Bioscience) and incubated at 4° C. for 15minutes. The cells were washed with BD Perm/Wash (BD Bioscience),intracellularly stained with FITC-labeled anti-IFN-γ antibody,PE-labeled anti-IL-4 antibody (BD Bioscience Pharmingen) and APC-labeledanti-IL-10 antibody (BD Bioscience Pharmingen), and intracellular triplestaining using fluorescence labeled isotype control antibodies wasperformed simultaneously (FIG. 17, upper panels). Then, the cells wereanalyzed by flow cytometry. As a result, in the cell group expressingthe cytokines, it was identified that there was almost no cellexpressing only IL-4 and the cell numbers were large in order of thecells expressing only IFNγ<the cells expressing both IL-10 and IFNγ<thecells expressing only IL-10 (FIG. 17, lower panels).

Example 6 <Inhibitory Effect of Liposome Containing Allergen andRegulatory Cell Ligand on IgE Antibody Production> 1. Preparation ofLiposome Containing Ovalbumin and α-Galactosyl Ceramide

L-α-Phosphatidylcholine, dioleoyl (DOPC; Wako Pure Chemical, 0.77 mg),0.83 mg of cholesteryl 3β-N-(dimethylaminoethyl)carbonate hydrochloride(DC-Chol; Sigma-Aldrich) and 0.029 mg of1,2-distearoyl-sn-glycero-3-phosethanolamine-N-[methoxy(polyethyleneglycol)-2000] (ammonium salt; PEG-PE; AVANTI POLAR-LIPIDS) weredissolved in 250 μL of chloroform/methanol (1:1) solvent. α-Galactosylceramide (0.16 mg, supplied from RIKEN Research Center for Allergy andImmunology) was separately dissolved in 250 μL of chloroform/methanol(1:1) solvent. Both were mixed and evaporated using the evaporator, andsubsequently dried overnight in the desiccator under vacuum.Subsequently, 200 μL of an aqueous solution containing 0.4 mg/mL ofovalbumin (OVA; Seikagaku Kogyo) was added thereto, the mixture wastreated using the sonicator for 10 minutes, and passed through themembrane having a pore size of 0.22 μm for sterilization. Then, theparticle sizes were selected by passing 25 times throughLiposoFast-Basic extruder (Avestin Inc.) equipped with a polycarbonatemembrane having a pore size of 100 nm. The OVA protein which had notbeen encapsulated in the liposome was eliminated by concentration of theliposomes in which OVA had been encapsulated using Amicon Ultra-4centrifugation filter (PL-100) (Millipore) and washing with purifiedwater, and finally the liposome was prepared into 800 μL of an aqueoussolution with purified water. This aqueous solution containing theliposome composition (Lipo-αGC+OVA) was analyzed on SDS electrophoresis,and consequently it was identified that the concentration of the OVAprotein was 50 μg/mL. All α-GalCer was supposed to be incorporated inthe liposome membrane, and the final concentration of α-GalCer in theLipo-αGC+OVA solution was rendered 200 μg/mL.

2. Induction of IL-10-Producing Regulatory CD4+ T Cells by Lipo-αGC+OVA

Lipo-αGC or Lipo-αGC+OVA (2 μg in terms of α-GalCer amount) wasintraperitoneally administered in the BDF1 (C57BL/6×DBA/2 F1) mouse,after 7 days, the spleen was removed, and the CD4⁺ T cells were preparedusing the magnetic microbeads (Miltenyi). Subsequently, antigenpresenting cells were prepared by irradiating spleen whole cells fromthe normal BDF1 mouse with radiation of 20 Gy. Then, 3 mL of the medium,the CD4⁺ T cells at 1.5×10⁶, the antigen presenting cells at 7.5×10⁶ andthe OVA protein at a final concentration of 100 μg/mL were added in onewell of a 6-well U bottom culture plate, and cultured in the incubatorcontaining 5% CO₂ at 37° C. for 6 days. Subsequently, the cells at 5×10⁵were cultured in the presence of PMA at a final concentration of 50ng/mL, 500 nM of ionomycin and 2 μM Monensin (Sigma-Aldrich) in theincubator containing 5% CO₂ at 37° C. for 4 hours. The cells werecollected, and stained with biotinylated anti-CD4 antibody andstreptoavidin-Per CP-Cy5.5 (BD Bioscience). Subsequently, the cells weresuspended in 100 μL of the BD Cytofix/Cytoperm solution

(BD Bioscience) and incubated at 4° C. for 15 minutes. The cells werewashed with BD Perm/Wash solution (BD Bioscience), then intracellularlystained with FITC-labeled anti-IFN-γ antibody, PE-labeled anti-IL-4antibody (BD Bioscience Pharmingen) and APC-labeled anti-IL-10 antibody(BD Bioscience Pharmingen), and analyzed by flow cytometry (FIG. 18). Asa result, in the CD4⁺ T cells derived from the spleen of the mouseadministered with Lipo-αGC without encapsulating OVA, 1.4% cellsexpressing only IL-4 and 1.1% cells expressing only IFNγ were detectedbut the CD4⁺ regulatory T cell population expressing only IL-10 or bothIFN-γ and IL-10 was scarcely detected. On the other hand, in theanalysis of the CD4⁺ T cells derived from the spleen of the mouseadministered with Lipo-αGC+OVA, the helper T cell population expressingonly IL-4 (1.0%) and only IFN-γ (9.9%), the IL-10-producing CD4⁺regulatory T cell population (14.1%) and the CD4⁺ regulatory T cellpopulation (9.1%) expressing both IL-10 and IFN-γ were detected. Fromthe above results, it was suggested that the allergen-containingLipo-αGC could in vivo differentiate and proliferate theallergen-specific CD4⁺ regulatory T cells having the inhibitory effecton the IgE production.

3. Inhibitory Effect of Lipo-αGC+OVA on Secondary Antibody Response inMice

BDF1 mice were primarily immunized with DNP-OVA (0.1 μg) and aluminiumhydroxide gel (2 mg). After 14 days, the antibody titers of anti-DNP-IgEantibody in blood were measured, and 3 groups (5 mice per group) wereprepared so that the average antibody titers were equivalent among them.On 21, 28 and 35 days after the primary immunization, the liposome alone(vehicle), Lipo-αGC or Lipo-αGC+OVA at 2 μg in terms of α-GalCer amountwas intraperitoneally administered. On the 42nd day after the primaryimmunization, the mice were boosted with DNP-OVA alone. On the 48th day,antibody titers of anti-DNP-IgE, anti-DNP-IgG1, anti-DNP-IgG2a, and thelevels of total IgE, total IgG1 and total IgG2a in blood were measuredby ELISA (FIG. 19). As a result, in the Lipo-αGC+OVA group, the antibodytiters of anti-DNP-IgE, anti-DNP-IgG1 and anti-DNP-IgG2a weresignificantly suppressed. On the other hand, in the Lipo-αGC groupcontaining no OVA, no significant suppression other than that in theantibody titer of anti-DNP-IgG1 was observed. From the above result, itwas suggested that Lipo-αGC containing the allergen can suppress thesecondary antibody response induced by the allergen.

4. Inhibitory Effect of Administration with α-GalactosylCeramide-Containing Liposome on In Vivo Production of Antigen SpecificIgE Antibody

The liposome alone, α-GC-liposome (α-GC: 2 pg/mouse) orα-GC-OVA-liposome (α-GC: 2 μg, OVA: 5 μg/mouse) was administered to BDF1mice sensitized with DNP-OVA (0.1 μg) or DNP-KLH (1 μg) and aluminiumhydroxide gel (2 mg), three times on the 21st, 28th and 35th days fromthe sensitization. The mice was boosted with DNP-OVA (0.1 μg) or DNP-KLH(1 μg) on the 42nd day from the sensitization. The amounts of anti-DNPIgE antibody, IgG1 antibody and IgG2a antibody in serum on the 49th daywere measured by ELISA.

As a result, in the group in which p60 -GC-OVA-liposome had been addedto the mice sensitized with DNP-OVA, the production of all IgE, IgG1 andIgG2a antibodies was significantly suppressed. However, in the group inwhich α-GC-liposome had been administered, the production of only IgG1and igG2a antibodies was significantly suppressed, and the production ofIgE antibody was not suppressed (FIG. 20).

From the above, it has been shown that the liposome containing α-GC andthe allergen can be effective for the inhibition of the allergy causedby the allergen.

5. Inhibitory Effect of Administration with α-GalactosylCeramide-Containing Liposome on In Vivo Secondary and Tertiary IgEAntibody Production

Saline, α-GC-liposome (α-GC: 2 μg/mouse), α-GC-OVA-liposome (α-GC: 2 μg,OVA: 5 μg/mouse) or the mixed solution of α-GC-liposome (α-GC: 2μg/mouse) and OVA (5 μg/mouse) was intraperitoneally administered toBDF1 mice sensitized with OVA (0.1 μg) and aluminium hydroxide gel (2mg), three times on the 21st, 28th and 35th day from the sensitization.The mice was boosted with OVA (0.1 μg) on the 52nd day after thesensitization, and boosted again on the 137th day. Blood samples werecollected before the sensitization and on the 14th, 49th, 59th, 125thand 145th days after the sensitization, and the amounts of anti-OVA IgEantibody in serum were measured by ELISA.

As a result, in the group in which α-GC-OVA-liposome had beenadministered, both secondary IgE antibody production after the firstboosting and tertiary IgE antibody production after the second boostingwere significantly suppressed, but in the group in which α-GC-liposomehad been administered, no suppression was observed. In the group inwhich the mixed solution of α-GC-liposome and OVA had been administered,the increase of IgE antibody titer before the first boosting wasidentified, and the subsequent secondary and tertiary IgE productionswere not significantly suppressed (FIG. 21).

From the above, it has been shown that the liposome containing α-GC andthe allergen can significantly suppress the allergy caused by theallergen compared with the combination of the α-GC-containing liposomewith the allergen.

INDUSTRIAL APPLICABILITY

The “liposome containing the regulatory cell ligand” of the presentinvention has the inhibitory actions on the activation action of thehelper T cell and on the IgE antibody production by inducing thedifferentiation/proliferation and the activation of the regulatorycells. Thus, the liposome of the present invention is useful as thepreventive agent and the therapeutic agent for the allergic diseasescaused by the type I allergic response in which the IgE antibody isdeeply involved, in particular atopic bronchial asthma, atopicdermatitis and allergic rhinitis such as pollinosis, and conjunctivitis.

The “α-galactosyl ceramide-containing liposome” is useful as the drugfor autoimmune diseases and graft-versus-host disease because theliposome can inhibit the differentiation/proliferation of the pathogenicT cells by selectively augmenting the immunosuppressive function of theNKT cells.

In addition, no side effect is necessary to be concerned for the drug ofthe present invention because the drug retains the molecule selectivelybound to the target cell and has the liposome including the regulatorycell ligand in the lipid membrane as the active ingredient.

1-11. (canceled)
 12. A pharmaceutical composition, comprising liposomescomprising KRN7000.
 13. A method of preventing or treating graft versushost disease (GVHD), comprising administering the pharmaceuticalcomposition of claim 12 to a subject in need of such prevention ortreatment.
 14. A method of preventing or treating rejection by atransplant patient, comprising administering the pharmaceuticalcomposition of claim 12 to such patient.
 15. A method of preventing ortreating autoimmune diseases, comprising administering thepharmaceutical composition of claim 12 to a subject in need of suchprevention or treatment.
 16. A method of preventing or treating anallergic disease, comprising administering the pharmaceuticalcomposition of claim 12 to a subject in need of such prevention ortreatment.
 17. The method of claim 16, wherein the allergic disease isselected from the group consisting of atopic bronchial asthma, allergicrhinitis, pollinosis, and atopic dermatitis.